Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 16/20 | 0.42 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.38 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.33 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.33 |
| ▸ | HTR3A | P46098 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24240280 | 0.82 | NOTUM (0.48) | NOTUMKEAP1MAP3K5CYP19A1CYP1A2 | |
| SCHEMBL4559009 | 0.75 | NOTUM (0.42) | NOTUMKEAP1MAP3K5CYP19A1CYP1A2 | |
| SCHEMBL30643761 | 0.75 | NOTUM (0.42) | NOTUMKEAP1MAP3K5CYP19A1CYP1A2 | |
| SCHEMBL4328742 | 0.73 | ALDH1A1 (0.47) | NOTUM | |
| SCHEMBL17104830 | 0.73 | — | — | |
| SCHEMBL30948251 | 0.72 | NOTUM (0.48) | NOTUMKEAP1MAP3K5CYP19A1 | |
| SCHEMBL27344929 | 0.70 | — | — | |
| SCHEMBL28191878 | 0.69 | NOTUM (0.41) | NOTUMKEAP1MAP3K5CYP19A1 | |
| SCHEMBL27163110 | 0.68 | NOTUM (0.41) | NOTUMKEAP1MAP3K5CYP19A1CYP1A2 | |
| SCHEMBL10447781 | 0.67 | NOTUM (0.78) | NOTUMKEAP1CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111247658-A | Transition metal complexes, polymers, mixtures, compositions and uses thereof | 广州华睿光电材料有限公司 | 2020-06-05 | — | — | CN | disclosed |
| EP-1907389-B1 | PROCESS FOR PREPARING TRIAZOLE SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES AND NOVEL SALT FORMS PRODUCED THEREIN | BRISTOL MYERS SQUIBB CO (US) | 2011-07-27 | — | — | EP | disclosed |
| US-7968718-B2 | Process for preparing triazole substituted azaindoleoxoacetic piperazine derivatives and novel salt forms produced therein | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-06-28 | — | — | US | disclosed |
| US-20100076191-A1 | PROCESS FOR PREPARING TRIAZOLE SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES AND NOVEL SALT FORMS PRODUCED THEREIN | BRISTOL-MYERS SQUIBB COMPANY | 2010-03-25 | — | — | US | disclosed |
| US-7601715-B2 | Process for preparing triazole substituted azaindoleoxoacetic piperazine derivatives and novel salt forms produced therein | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-10-13 | — | — | US | disclosed |
| EP-1907389-A2 | PROCESS FOR PREPARING TRIAZOLE SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES AND NOVEL SALT FORMS PRODUCED THEREIN | Bristol-Myers Squibb Company (US) | 2008-04-09 | — | — | EP | disclosed |
| WO-2007002308-A9 | PROCESS FOR PREPARING TRIAZOLE SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES AND NOVEL SALT FORMS PRODUCED THEREIN | BRISTOL MYERS SQUIBB CO (US) | 2007-03-01 | — | — | WO | disclosed |
| WO-2007002308-A2 | PROCESS FOR PREPARING TRIAZOLE SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES AND NOVEL SALT FORMS PRODUCED THEREIN | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-01-04 | — | — | WO | disclosed |
| US-20060293304-A1 | Process for preparing triazole substituted azaindoleoxoacetic piperazine derivatives and novel salt forms produced therein | BRISTOL-MYERS SQUIBB COMPANY | 2006-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060293304-A1 | Process for preparing triazole substituted azaindoleoxoacetic piperazine derivatives and novel salt forms produced therein | NAT1, NISCH, AZI2 | NOTUM 2897/4885KEAP1 4255/4885MAP3K5 877/4885 |
| US-20100076191-A1 | PROCESS FOR PREPARING TRIAZOLE SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES AND NOVEL SALT FORMS PRODUCED THEREIN | NAT1, NISCH, AZI2 | NOTUM 2897/4885KEAP1 4255/4885MAP3K5 877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.